← All trials
NCT02703363
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2016
- Primary completion
- Aug 1, 2018
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 240
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Government of PakistanLead sponsor
- Dow University of Health SciencesCollaborator
- University of ManchesterCollaborator
- Stanley Medical Research InstituteCollaborator
- Abbasi Shaheed HospitalCollaborator
- Rawalpindi Medical College, PakistanCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.